BACKGROUND: Cardiac rehabilitation (CR) has numerous benefits, including reduction of mortality and cardiovascular events, in patients with coronary artery disease (CAD). However, the long-term effect of phase III CR in elderly patients with stable CAD is still unknown. METHODS AND RESULTS: The 111 elderly male CAD patients (>or=65 years), including 37 subjects participating in supervised CR for 6 months and 74 age-matched controls, were analyzed. The patients were followed for up to 3,500 days, until the occurrence of death or 1 of the following major adverse cardiovascular events (MACE): cardiovascular death, acute coronary syndrome, refractory angina requiring revascularization, admission for congestive heart failure, or stroke. All-cause mortality tended to be lower in the CR group than in the Control group (14% vs 28%, P=0.081). The MACE incidence was significantly lower in the CR group than in the Control group (30% vs 62%, P=0.001). Multivariate Cox proportional hazard analysis showed that the MACE incidence was significantly lower in the CR group than in the Control group [adjusted hazard ratio 0.43 (95% confidence interval 0.20-0.91), P=0.027]. CONCLUSIONS: Phase III CR has the beneficial effect of reducing cardiovascular events even in elderly patients with stable CAD.
BACKGROUND: Cardiac rehabilitation (CR) has numerous benefits, including reduction of mortality and cardiovascular events, in patients with coronary artery disease (CAD). However, the long-term effect of phase III CR in elderly patients with stable CAD is still unknown. METHODS AND RESULTS: The 111 elderly male CAD patients (>or=65 years), including 37 subjects participating in supervised CR for 6 months and 74 age-matched controls, were analyzed. The patients were followed for up to 3,500 days, until the occurrence of death or 1 of the following major adverse cardiovascular events (MACE): cardiovascular death, acute coronary syndrome, refractory angina requiring revascularization, admission for congestive heart failure, or stroke. All-cause mortality tended to be lower in the CR group than in the Control group (14% vs 28%, P=0.081). The MACE incidence was significantly lower in the CR group than in the Control group (30% vs 62%, P=0.001). Multivariate Cox proportional hazard analysis showed that the MACE incidence was significantly lower in the CR group than in the Control group [adjusted hazard ratio 0.43 (95% confidence interval 0.20-0.91), P=0.027]. CONCLUSIONS: Phase III CR has the beneficial effect of reducing cardiovascular events even in elderly patients with stable CAD.
Authors: Pietro Felice Tomazini Nesello; Olga Tairova; Maria Tairova; Lucas Graciolli; Allan Baroni; Eduardo Comparsi; Thiago De Marchi Journal: Open Access Maced J Med Sci Date: 2016-11-25
Authors: Catherine Giuliano; Belinda J Parmenter; Michael K Baker; Braden L Mitchell; Andrew D Williams; Katie Lyndon; Tarryn Mair; Andrew Maiorana; Neil A Smart; Itamar Levinger Journal: Clin Med Insights Cardiol Date: 2017-06-12
Authors: Linda Long; Lindsey Anderson; Alice M Dewhirst; Jingzhou He; Charlene Bridges; Manish Gandhi; Rod S Taylor Journal: Cochrane Database Syst Rev Date: 2018-02-02
Authors: Bernhard Rauch; Annett Salzwedel; Birna Bjarnason-Wehrens; Christian Albus; Karin Meng; Jean-Paul Schmid; Werner Benzer; Matthes Hackbusch; Katrin Jensen; Bernhard Schwaab; Johann Altenberger; Nicola Benjamin; Kurt Bestehorn; Christa Bongarth; Gesine Dörr; Sarah Eichler; Hans-Peter Einwang; Johannes Falk; Johannes Glatz; Stephan Gielen; Maurizio Grilli; Ekkehard Grünig; Manju Guha; Matthias Hermann; Eike Hoberg; Stefan Höfer; Harald Kaemmerer; Karl-Heinz Ladwig; Wolfgang Mayer-Berger; Maria-Inti Metzendorf; Roland Nebel; Rhoia Clara Neidenbach; Josef Niebauer; Uwe Nixdorff; Renate Oberhoffer; Rona Reibis; Nils Reiss; Daniel Saure; Axel Schlitt; Heinz Völler; Roland von Känel; Susanne Weinbrenner; Ronja Westphal Journal: J Clin Med Date: 2021-05-19 Impact factor: 4.241